Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

TOMBOLA: atezolizumab at ctDNA relapse after radical cystectomy

Phase 2 study that starts atezolizumab when circulating tumor DNA becomes positive after radical cystectomy for muscle-invasive bladder cancer, before or alongside radiographic metastases.

Aarhus University Hospital